These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 28359805)

  • 21. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photodynamic Treatments for Disseminated Cancer Metastases Using Fiber-Optic Technologies.
    Kercher EM; Spring BQ
    Methods Mol Biol; 2022; 2451():185-201. PubMed ID: 35505019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
    de Jong JM; Hoogendam JP; Braat AJAT; Zweemer RP; Gerestein CG
    Gynecol Oncol; 2021 Aug; 162(2):517-525. PubMed ID: 34053747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control.
    Petrillo M; Anchora LP; Scambia G; Fagotti A
    Oncologist; 2016 May; 21(5):532-4. PubMed ID: 27009941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
    He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
    Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
    Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
    Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
    Halkia E; Spiliotis J
    J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery.
    Paik ES; Lee YY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Bae DS
    Aust N Z J Obstet Gynaecol; 2016 Dec; 56(6):639-647. PubMed ID: 27611447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
    Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effect of photodynamic therapy with a novel targeted photosensitizer on cervical carcinoma.
    Li PX; Mu JH; Xiao HL; Li DH
    Oncol Rep; 2015 Jan; 33(1):125-32. PubMed ID: 25376180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
    Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
    Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
    Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.
    Frenel JS; Leux C; Pouplin L; Ferron G; Berton Rigaud D; Bourbouloux E; Dravet F; Jaffre I; Classe JM
    J Surg Oncol; 2011 Jan; 103(1):10-6. PubMed ID: 21031424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly selective targeting of ovarian cancer with the photosensitizer PEG-m-THPC in a rat model.
    Hornung R; Fehr MK; Monti-Frayne J; Krasieva TB; Tromberg BJ; Berns MW; Tadir Y
    Photochem Photobiol; 1999 Oct; 70(4):624-9. PubMed ID: 10546556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical activity of melflufen (J1) in ovarian cancer.
    Carlier C; Strese S; Viktorsson K; Velander E; Nygren P; Uustalu M; Juntti T; Lewensohn R; Larsson R; Spira J; De Vlieghere E; Ceelen WP; Gullbo J
    Oncotarget; 2016 Sep; 7(37):59322-59335. PubMed ID: 27528037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.
    Tempfer CB; Celik I; Solass W; Buerkle B; Pabst UG; Zieren J; Strumberg D; Reymond MA
    Gynecol Oncol; 2014 Feb; 132(2):307-11. PubMed ID: 24275155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
    Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
    Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.